BeStock  
Stocks › Biotechnology › BCAX

Bicara Therapeutics BCAX

US equityMarket cap rank #3186Biotechnology
$16.42 −$0.14 (-0.85%)
Pre-market · Oct 8, 8:20 am ET · After hours $16.42 0.00%
Open$16.44
Prev close$16.56
Day range$16.25 – $17.11
Volume915.6K
Market cap$1.09B
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±6.5%last 3 reports
Closed higher2 of 367% of the time
Best reaction+3.6%
Worst reaction-14.3%

Stock move on the day after each report

+3.6%2025/Q4+1.5%2026/Q1-14.3%2026/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q211 Aug 2026Pre Market±11.7%-14.32%Bigger than priced
2026/Q111 May 2026Pre Market–+1.51%–
2025/Q430 Mar 2026Pre Market–+3.65%–

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Fundamentals

Full statements →

Latest reported quarter: Q2, ended Jun 2026

Revenue$0.00
Operating profit-$59.95M-87.2% YoY
Net profit-$55.44M-102.4% YoY
Diluted EPS-$0.82-64.0% YoY
Free cash flow-$44.27M-73.0% YoY
Operating cash flow-$44.21M

Revenue, last 8 quarters

$0.0Sep '24$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26

Net profit, last 8 quarters

$-17.5MSep '24$-21.0MDec '24$-36.8MMar '25$-27.4MJun '25$-36.3MSep '25$-37.4MDec '25$-56.2MMar '26$-55.4MJun '26

Profitability & balance sheet

Return on equity-41.0%
Return on assets-38.4%
Return on invested capital-43.1%
Current ratio11.59
Liabilities / assets8.5%
Cash & investments$497.26M
Total debt$0.00
Net cash (debt)$497.26M

Discussion

No comments yet — be the first to weigh in on BCAX.

Leave a comment

Scroll to Top